Loading clinical trials...
Loading clinical trials...
Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Conditions
Interventions
Placebo
Atorvastatin
Locations
5
United States
Winship Cancer Institute at Emory University
Atlanta, Georgia, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Wilmot Cancer Institute at the University of Rochester Medical Center in New Yor
Rochester, New York, United States
Inova Schar Cancer Center
Fairfax, Virginia, United States
Start Date
July 10, 2024
Primary Completion Date
August 1, 2028
Completion Date
August 31, 2030
Last Updated
March 9, 2026
NCT07209189
NCT06477692
NCT04585750
NCT07457346
NCT06636188
NCT07065630
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions